Oculis Completes Randomization in PREDICT-1 Trial of Licaminlimab for Dry Eye Disease

• Oculis completed randomization in PREDICT-1, its first genotype-guided registrational trial of licaminlimab for dry eye disease.
• The study enrolled 176 patients; two-thirds carry the targeted TNFR1 genetic variant associated with stronger responses in earlier trials.
• Topline results are expected around year-end 2026; the trial evaluates symptom relief versus vehicle.
• Earlier Phase 2 studies showed improvements in dry eye signs and symptoms, with greater responses among patients carrying the variant.
• The potential US market includes 1.3 million to 1.9 million patients with moderate-to-severe disease carrying the relevant variant.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190200PRIMZONEFULLFEED1001278538) on October 19, 2026, and is solely responsible for the information contained therein.